Detalle de acción
EVMN
Evommune, Inc.
-
-
-
-
| Capitalización | - |
|---|---|
| Volumen | - |
| Rango del día | - |
| Ingresos (TTM) | - |
| Ingreso neto | - |
| EPS | - |
| Acciones en circulación | - |
| PE | - |
| PE forward | - |
| Dividendo | - |
| Fecha ex-dividendo | - |
| Open | - |
| Close anterior | - |
| Rango 52 semanas | - |
| Beta | - |
| Analistas | - |
| Precio objetivo | - |
| Fecha de resultados | - |
Cargando...
Acerca de
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC.
The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Industria
Biotecnología
Sector
Salud
Fecha de IPO
Nov 6, 2025
Empleados
48
Bolsa
NYSE
Sitio web
evommune.com
PUBLICIDAD